Myriad has changed a lot over the past 20 years. We’ve gone from being a single product company in just the United States to a company with 15 products on
the market or in development and operations around the world. We are transforming into a leader in the personalized medicine industry with our innovative,
high-quality molecular diagnostics. And today, for the first time since our founding, we’re updating our logo:

  • The new logo consists of elements that are true to the heritage of our company and our passion for patients.
  • The icon
    is a modernized helix that symbolizes our pioneering science and world-class expertise in DNA sequencing, RNA analysis and proteomics.
  • The tagline, “When Decisions Matter” reflects our commitment to being trusted advisors to patients and physicians earned by a relentless pursuit of perfection and
    professional integrity.


Click here to learn more about “When Decisions Matter” from Mark Capone, CEO of Myriad Genetics

Myriad Genetics at J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st annual J.P. Morgan (JPM) Healthcare Conference.